Polaris Partners’ Post

Looking forward to gaining more insight on the activity going on in Psychedelic research tomorrow!

Improving autoimmune clinical trial inclusion requires creative thinking, explains Dr. Stacie Bell with Lupus Therapeutics in this webinar clip. Watch the full #SWHRtalksAutoimmune webinar online here: https://ow.ly/JWm150SGeke

Don't forget to join Vigeo Therapeutics COO Dr. Jing Watnick updating the Fifth Annual Glioblastoma Drug Development Summit TODAY at 1:30 PM EDT today (March 28) in Boston, MA. Dr. Watnick will give an overview of #VT1021 in our Ph1/2 program in GBM as well as the future use of #VT1021 in attacking the roots of Neuro-inflammatory disease #GBM #Glioblastoma #NeurodegenerativeDisease #NeuroInflammatoryDisease #GBMSummit

On October 10, 2024, the Food and Drug Administration approved inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic #breastcancer, as detected by an #FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. FDA also approved the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer for treatment with inavolisib with palbociclib and fulvestrant. FDA #precisionmedicine #cancercare

On June 4th, Resolution Therapeutics CEO Amir Hefni, and CFO Simon Ramsden will attend the Jefferies Global Healthcare Conference 2024 in New York. They will be meeting with investors to discuss their innovative macrophage cell therapies, aimed at transforming the treatment of inflammatory organ diseases. If you are attending and would like to learn more about Resolution Therapeutics or schedule a meeting, please get in touch! Full press release in the comments below. #ResolutionTherapeutics #JefferiesHealthcare #Macrophages

FDA approves Thermo Fisher Scientific's Ion Torrent Oncomine Dx Target Test as companion diagnostic for Voranigo in IDH-mutant glioma. This breakthrough enables targeted therapy for Grade 2 astrocytoma/oligodendroglioma patients 12+. "Identifying key driver mutations is essential to help the right patients find the right treatment, at the right time." - David Lee, CEO Servier Pharmaceuticals https://lnkd.in/eceBs82Z 📰 Stay ahead in healthcare by following Practical Patient Care on LinkedIn! Get the latest news and insights on patient care and clinical advancements. Join our community to stay informed and enhance your knowledge. Follow us today! #PracticalPatientCare #PrecisionMedicine #BrainCancer #ClinicalDiagnostics #OncologyInnovation

At Artax Biopharma, we are developing first-in-class Nck modulators to treat T cell mediated autoimmune disease such as #psoriasis, #atopicdermatitis, and more. We're excited by the progress we've been making in the development of our first novel mechanism, AX-158, as we rapidly approach phase 2 trials for psoriasis treatment with first results expected in Q4 2024. We are simultaneously developing additional Nck modulator candidates for #autoimmunediseases with AX-194 undergoing preclinical testing to enter Phase 1 trials. Learn more about our candidate pipeline on our recently updated website here: https://lnkd.in/eqq3eSTK #clinincaltrials #immunology

🚨 FDA Issues Black Box Warning for CAR-T Therapy: A Critical Update for the Life Sciences Industry 🚨 The FDA has mandated a black box warning for CAR-T cell immunotherapies, a specialized treatment for certain blood cancers. This decision follows investigations into reports of T-cell malignancies associated with these therapies. 🔍 Companies Affected: Bristol-Myers Squibb Juno Therapeutics Janssen Biotech of Johnson & Johnson Novartis Kite Pharma 📌 Key Points: Black box warning, the most serious safety alert, indicates the potential for the therapy itself to cause cancer. FDA emphasizes that overall benefits outweigh the risks for approved uses but stresses the importance of patient awareness. #LifeSciences #QualityControl #QualityAssurance #FDAUpdate #CAR_TTherapy

Not a National Association of Specialty Pharmacy (NASP)member? Want to get a glimpse of what you are missing? NASP is pleased to invite you to a webinar presented by Mirati Therapeutics, Inc. on Thursday, February 8 at 1pm EST titled, “How Is the Treatment of Patients with KRAS G12C-Mutated Advanced NSCLC Evolving?” Join speaker Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP, University of Illinois Hospital and Health Sciences System, for a review of KRAS G12C inhibition in NSCLC, with a focus on Krazati™ (adagrasib), a KRAS G12C Inhibitor.

🚨 A new targeted drug combination treatment, described as a ‘step-change in care’ for #cancer patients, has today been recommended by NICE - National Institute for Health and Care Excellence. ✅ Dabrafenib, marketed as Finlee, in combination with trametinib, which is sold as Spexotras, (both made by Novartis) is being recommended in final draft guidance for treating BRAF V600E mutation-positive glioma. 📈 Clinical trials show the new treatment stalls the tumour growth in people for an average of more than two years – three times longer than current drugs. 🗣️ Read on to find out NHS England perspective 👉  https://lnkd.in/ePuUJAh3 #pharma #lifesciences #braincancer #clinicaltrial